Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma: multicohort, phase 2 keynote-087 study.
Authors
Moskowitz, CZinzani, P
Fanale, M
Armand, P
Johnson, N
Ribrag, V
Radford, John A
von Tresckow, B
Tomita, A
Shipp, M
Wang, Y
Ricart, A
Balakumaran, A
Chen, R
Affiliation
Memorial Sloan Kettering Cancer Center, New York, USAIssue Date
2016